Generated by DeepSeek V3.2| fluorine-18 | |
|---|---|
| Isotope | fluorine-18 |
| Mass number | 18 |
| Halflife | 109.771(20) min |
| Decay mode1 | β+ |
| Decay energy1 | 0.6335 |
| Decay product1 | oxygen-18 |
| Decay mode2 | Electron capture |
| Decay product2 | oxygen-18 |
fluorine-18 is a radioactive isotope of fluorine with a half-life of approximately 110 minutes. It decays primarily by positron emission to stable oxygen-18, making it a crucial tool in nuclear medicine. Its most significant application is in the synthesis of fluorodeoxyglucose (FDG) for use in positron emission tomography (PET) imaging, a cornerstone of modern oncology and neurology.
Fluorine-18 is a pure positron emitter, with 97% of its decays occurring via β+ emission and the remaining 3% via electron capture. The emitted positron has a maximum energy of 0.6335 MeV and, upon annihilation with an electron, produces two 511 keV gamma rays emitted in opposite directions, a key physical principle for PET detection. Its relatively short half-life necessitates rapid synthesis and use but minimizes radiation dose to patients. The isotope's chemistry allows it to be incorporated into a wide variety of biomolecules without drastically altering their biological behavior, a concept pioneered by researchers like Michael J. Welch.
Fluorine-18 is almost exclusively produced in a cyclotron via nuclear reactions on enriched stable isotopes. The most common production route is the proton bombardment of oxygen-18-enriched water, using the 18O(p,n)18F nuclear reaction, a method refined at institutions like Brookhaven National Laboratory. An alternative method involves irradiating a neon-20 gas target with deuterons via the 20Ne(d,α)18F reaction. Following irradiation, the fluorine-18, typically in the form of fluoride ion or molecular fluorine, is extracted using automated synthesis modules in facilities adhering to strict Good Manufacturing Practice guidelines. Major suppliers include PETNET Solutions and IBA RadioPharma Solutions.
The paramount application of fluorine-18 is in the creation of fluorodeoxyglucose (FDG), a glucose analog used in PET imaging to visualize metabolic activity in tissues. This is fundamental in oncology for cancer staging, assessing treatment response in diseases like Hodgkin lymphoma, and detecting recurrence. In neurology, FDG-PET aids in the diagnosis of Alzheimer's disease, epilepsy, and Parkinson's disease. Beyond FDG, fluorine-18 labels other important radiopharmaceuticals such as sodium fluoride for bone imaging, florbetapir for amyloid plaque detection in the brain, and fluorodopa for studying the dopaminergic system. Research into new tracers is ongoing at centers like the University of California, Los Angeles and the Johns Hopkins School of Medicine.
As a radioactive material, fluorine-18 must be handled in accordance with regulations set by bodies like the Nuclear Regulatory Commission in the United States and the International Atomic Energy Agency. Personnel in cyclotron and radiopharmacy facilities use lead or tungsten shielding and remote handling tools behind hot cells to minimize exposure. Radiation monitoring with devices like Geiger-Müller counters and personal dosimeters is mandatory. The short half-life means waste decays quickly, simplifying disposal. Emergency procedures are designed to contain spills and protect workers, following guidelines from organizations like the National Council on Radiation Protection and Measurements.
The discovery of fluorine-18 is attributed to Ernest Lawrence and his team using the cyclotron at the University of California, Berkeley in the late 1930s. Its potential for medical tracing was recognized in the 1960s, but the pivotal breakthrough came in 1976 with the development of fluorodeoxyglucose by a team led by Tatsuo Ido at the Brookhaven National Laboratory, with key contributions from Al Wolf and Joanna S. Fowler. The subsequent coupling of FDG with PET imaging, advanced by scientists such as Michael E. Phelps and Henry N. Wagner Jr., revolutionized diagnostic medicine. The 1990s and 2000s saw the widespread clinical adoption of FDG-PET, endorsed by agencies like the Centers for Medicare & Medicaid Services, solidifying fluorine-18's role in global healthcare.
Category:Fluorine Category:Positron emission tomography Category:Medical isotopes